Avadel Pharmaceuticals to Announce Q1 2024 Financial Results and Corporate Update on May 8

DUBLIN, Ireland, May 01, 2024-- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company dedicated to transforming medical treatments and improving patient lives, announced it will host a conference call and live webcast on Wednesday, May 8, 2024, at 8:30 a.m. ET. The purpose of the call is to provide an update on corporate activities and discuss the financial results for the first quarter that ended on March 31, 2024.

To participate in the conference call, investors can dial +1 (800) 715-9871 for those in the U.S. and Canada, or +1 (646) 307-1963 for international callers, using the conference ID 2270373. Additionally, a live audio webcast of the call will be available through the investor relations section of Avadel’s website. Post-conference, a replay of the webcast will be accessible on the company's website for a period of 90 days.

Avadel Pharmaceuticals plc is a biopharmaceutical entity that focuses on transforming medicines to significantly enhance patient lives. The company's strategy involves employing innovative approaches to develop medications that address the limitations and challenges presented by current treatment options. Avadel’s key commercial product, LUMRYZ™, has been approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for treating cataplexy or excessive daytime sleepiness (EDS) in adults diagnosed with narcolepsy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!